Innovent Biologics, Inc. (Innovent) announced unaudited product revenue of more than RMB 8.20 billion for the six months ended 30 June 2026, representing year-on-year growth exceeding 55%. Second-quarter revenue alone surpassed RMB 4.30 billion, up approximately 60% from the same period in 2025, underscoring the effectiveness of the company’s dual-engine growth strategy.

Growth drivers • General biomedicine delivered “exceptional” expansion, led by mazdutide, SINTBILO (tafolecimab) and SYCUME (teprotumumab N01), which collectively formed a core revenue pillar. • Oncology sales remained robust. Five tyrosine kinase inhibitor (TKI) therapies newly listed on China’s National Reimbursement Drug List achieved rapid market penetration and became increasingly material contributors. • The strategic partnership with Eli Lilly for Verzenios (abemaciclib) broadened Innovent’s reach into the breast-cancer segment, reinforcing its commercial footprint.

Pipeline and partnerships Innovent advanced three core innovative assets into global Phase 3 trials during the first half and continued to diversify its next-generation pipeline across oncology, cardiovascular and metabolism, autoimmune diseases and ophthalmology. More than 20 collaborative programmes—including five co-development and co-commercialisation arrangements—with multinational partners such as Pfizer, Lilly, Takeda and Roche further validated the company’s R&D capabilities.

Strategic outlook Management highlighted ongoing efforts to leverage domestic revenue momentum and an expanding global pipeline to accelerate international growth, aiming to establish Innovent as a world-class biopharmaceutical company.

(The financial figures are based on internal management accounts and unaudited data disclosed by Innovent Biologics in its 5 August 2026 announcement.)